Literature DB >> 8981329

Developmental regulation of perlecan gene expression in aortic smooth muscle cells.

M C Weiser1, J K Belknap, S S Grieshaber, M G Kinsella, R A Majack.   

Abstract

Heparan sulfate proteoglycans (HSPGs) are believed to act as potent endogenous regulators of vascular smooth muscle cell (SMC) replication, migration, gene expression and differentiation. Here we describe the pattern of expression of perlecan, the predominant basement membrane HSPG, during aortic development in the rat. Expression of perlecan mRNA and protein in the aortic SMC was first significantly observed at day e19 (day 19 of embryonic development), a time which marks a dramatic switch in SMC replication rate and growth phenotype. Expression of perlecan message and protein was high throughout fetal and early neonatal life, and it remained readily detectable in the adult aorta. Using a double-labeling technique (in situ hybridization for perlecan message coupled with bromodeoxyuridine immunohistochemistry), we determined the relationship between DNA synthesis and perlecan mRNA expression in individual SMC at days e17-e21; we found that perlecan gene expression was largely limited to non-replicating cells. Consistent with the in vivo data, perlecan mRNA was undetectable in cultured e17 SMC by Northern or RT-PCR analysis, while in cultured adult SMC, perlecan mRNA was significantly higher in non-replicating (serum-starved) cultures compared to replicating cultures. Treatment of growth-arrested adult SMC cultures with heparin caused a further accumulation in perlecan mRNA levels. The data suggest that the expression of perlecan by vascular SMC is regulated by apparent developmental age as well as by cellular growth state. The developmentally times expression of perlecan in the aortic wall may contribute to the establishment and/or maintenance of vascular SMC differentiation and quiescence.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8981329     DOI: 10.1016/s0945-053x(96)90136-5

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  8 in total

Review 1.  Extra-cellular matrix in vascular networks.

Authors:  George Bou-Gharios; Markella Ponticos; Vineeth Rajkumar; David Abraham
Journal:  Cell Prolif       Date:  2004-06       Impact factor: 6.831

2.  Do two mutually exclusive gene modules define the phenotypic diversity of mammalian smooth muscle?

Authors:  Erik Larsson; Sean E McLean; Robert P Mecham; Per Lindahl; Sven Nelander
Journal:  Mol Genet Genomics       Date:  2008-05-29       Impact factor: 3.291

3.  Perlecan regulates Oct-1 gene expression in vascular smooth muscle cells.

Authors:  M C Weiser; N A Grieshaber; P E Schwartz; R A Majack
Journal:  Mol Biol Cell       Date:  1997-06       Impact factor: 4.138

4.  The role of vascular-derived perlecan in modulating cell adhesion, proliferation and growth factor signaling.

Authors:  Megan S Lord; Christine Y Chuang; James Melrose; Michael J Davies; Renato V Iozzo; John M Whitelock
Journal:  Matrix Biol       Date:  2014-02-06       Impact factor: 11.583

Review 5.  Perlecan and tumor angiogenesis.

Authors:  Xinnong Jiang; John R Couchman
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

6.  Perlecan up-regulation of FRNK suppresses smooth muscle cell proliferation via inhibition of FAK signaling.

Authors:  Heather A Walker; John M Whitelock; Pamela J Garl; Raphael A Nemenoff; Kurt R Stenmark; Mary C M Weiser-Evans
Journal:  Mol Biol Cell       Date:  2003-01-26       Impact factor: 4.138

7.  Distinct effects of glucose and glucosamine on vascular endothelial and smooth muscle cells: evidence for a protective role for glucosamine in atherosclerosis.

Authors:  Wenlan Duan; Latha Paka; Sivaram Pillarisetti
Journal:  Cardiovasc Diabetol       Date:  2005-10-05       Impact factor: 9.951

8.  Extracellular matrix molecules facilitating vascular biointegration.

Authors:  Steven G Wise; Anna Waterhouse; Praveesuda Michael; Martin K C Ng
Journal:  J Funct Biomater       Date:  2012-08-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.